Alergologia Polska - Polish Journal of Allergology

Full text

2/2026 vol. 13
Special paper

Single-inhaler triple therapy (ICS/LA BA/LA MA) in asthma management: 2026 update of the Polish expert position statement

Adam Barczyk 1
,
Adam Antczak 2
,
Adam J. Białas 3
,
Małgorzata Czajkowska-Malinowska 4
,
Rafał Dobek 5
,
Radoslaw Gawlik 6
,
Marek Kulus 7
,
Piotr Kuna 8
,
Maciej Kupczyk 8
,
Iwona Poziomkowska-Gęsicka 9
,
Paweł Śliwiński 5

  1. Department and Clinic of Pneumology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland

  2. Department of General and Oncological Pulmonology, Medical University of Lodz, Poland

  3. Department of Pneumology, Medical University of Lodz, Poland

  4. Department of Pulmonary Diseases and Respiratory Failure with the Subunit of Noninvasive Ventilation and the Subunit of Sleep-Related Breathing Disorders, Kuyavian-Pomeranian Pulmonology Center, Bydgoszcz, Poland

  5. 2nd Department of Respiratory Medicine, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

  6. Department of Internal Medicine, Allergy and Clinical Immunology, Medical University of Silesia, Katowice, Poland

  7. Department of Pediatric Pulmonology and Allergology, Medical University of Warsaw, Poland

  8. Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Poland

  9. Division of Clinical Allergology, Pomeranian Medical University, Szczecin, Poland

Alergologia Polska – Polish Journal of Allergology 2026; 13, 2: 69–79


DOI: https://doi.org/10.5114/pja.2026.162391
Data publikacji online: 2026/06/23
Article file
Single-inhaler.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Śliwiński P, Antczak A, Barczyk A, et al. 2024 update on position statement by experts from the Polish Society of Allergology and the Polish Respiratory Society on the evaluation of efficacy and effectiveness of single inhaler triple therapies in asthma treatment. Adv Respir Med 2024; 92: 452-65.
  2. Bårnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care 2015; 60: 455-68.
  3. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2025. Available from: www.ginasthma.org.
  4. Asthma report. Available from: https://koalicja.pta.med.pl/wp-content/Astma_Raport_FINAL.pdf
  5. Shim J, Ahn K, Kim M, Cho Y. Lower baseline FEV1 is associated with greater FEV1 improvement after tiotropium add-on in uncontrolled asthma. Medicine 2025; 104: e44912.
  6. Agache I, Adcock IM, Akdis CA, et al. The bronchodilator and anti-inflammatory effect of long-acting muscarinic antagonists in asthma: an EAACI position paper. Allergy: Eur J Allergy Clin Immunol 2025; 80: 380-94.
  7. Canonica GW, Blasi F, Paggiaro P, et al. Severe Asthma Network Italy definition of clinical remission in severe asthma: a Delphi consensus. J Allergy Clin Immunol Pract 2023; 11: 3629-37.
  8. Canonica GW, Blasi F, Paggiaro P, et al. Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: evidence from the Severe Asthma Network in Italy (SANI). World Allergy Organ J 2025; 18: 101016.
  9. Jeannetot D, Ridder MD, Mosseveld M, et al. Treatment choice for adult patients with moderate-to-severe asthma: the TAILOR study. ERJ Open Res 2025; 11: 00869-2024.
  10. Matera MG, Cazzola M, Rogliani P, Patella V. An update on long-acting muscarinic agents for asthma therapy. Exp Rev Respir Med 2025; 19: 407-21.
  11. Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet 2019; 394: 1737-49.
  12. Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med 2020; 8: 1000-12.
  13. Ridolo E, Milanese M, Barone A, et al. Extrafine formulation of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurized metered-dose inhaler in the treatment of asthma: a review. Ther Adv Respir Dis 2025; 19: 17534666251332076.
  14. Usmani OS, Baldi S, Warren S, et al. Lung deposition of inhaled extrafine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide in healthy volunteers and asthma: the STORM study. J Aerosol Med Pulm Drug Deliv 2022; 35: 179-85.
  15. Gessner C, et al. Long-term asthma control with beclometasone/formoterol/glycopyrronium: 12-month results of the TriMaximize study. In: Proceedings of the European Respiratory Society Congress 2025.
  16. Katsaounou P, Korkontzelou A, Papapostolou E, et al. Effectiveness of extrafine single-inhaler triple therapy (efSITT) on asthma control one year post-treatment stratified by smoking status: the TRIANGLE study. European Respir J 2025; 66 (suppl 69): PA5701.
  17. Papi A, Singh D, Virchow JC, et al. Normalisation of airflow limitation in asthma: post-hoc analyses of TRIMARAN and TRIGGER. Clin Transl Allergy 2022; 12: e12145.
  18. Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med 2021; 9: 69-84.
  19. Quaranta VN, Montagnolo F, Portacci A, et al. Steady quiet asthma without biologics: one-year outcomes of single-inhaler triple therapy for severe asthma with small airway dysfunction. J Clin Med 2025; 14: 5602.
  20. Menzella F, Galeone C, Ghidoni G, et al. The pharmacoeconomics of state-of-the-art drug treatments for asthma: a systematic review. Multidiscip Respir Med 2021; 16: 787.
  21. Orlovic M, Magni T, Lukyanov V, et al. Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England. Respir Med 2022; 201: 106934.
  22. Vlachaki I, Donhauser S, Madoni A, et al. Cost-effectiveness analysis comparing single-inhaler extrafine beclomethasone/formoterol/glycopyrronium bromide with other single-inhaler triple therapies in adult patients with uncontrolled asthma in England. Health Econom Rev 2025; 15: 42.
  23. Trimbow: product characteristics. Available from: https://www.ema.europa.eu/pl/documents/product-information/trimbow-epar-product-information_pl.pdf [date of access: 5th March 2026].
  24. Enerzair Breezhaler: product characteristics. Available from: https://ec.europa.eu/health/documents/community-register/2020/20200703148265/anx_148265_pl.pdf [date of access: 5th March 2026].
  25. Braido F, Vlachaki I, Nikolaidis G, et al. Single inhaler with beclometasone, formoterol and glycopyrronium versus triple therapies in adults with uncontrolled asthma: a systematic review and meta-analysis. Sci Rep 2025; 15: 4191.
Copyright: © Polish Society of Allergology This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications